Patents by Inventor POTTAYIL GOVINDAN NAIR SASIKUMAR

POTTAYIL GOVINDAN NAIR SASIKUMAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS
    Publication number: 20250144082
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: January 9, 2025
    Publication date: May 8, 2025
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Nagaraj Gowda
  • CRYSTALLINE FORMS OF 3-SUBSTITUTED 1,2,4- OXADIAZOLE
    Publication number: 20250136562
    Abstract: The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.
    Type: Application
    Filed: November 22, 2024
    Publication date: May 1, 2025
    Inventors: Pottayil Govindan Nair Sasikumar, Seetharamaiah Setty Naremaddepalli
  • Combination of small molecule CD-47 inhibitors with other anti-cancer agents
    Patent number: 12268670
    Abstract: The present invention relates to a composition of a CD47-SIRP? blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP? blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP? blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: April 8, 2025
    Assignee: AURIGENE ONCOLOGY LIMITED
    Inventors: Muralidhara Ramachandra, Pottayil Govindan Nair Sasikumar, Girish Chandrappa Daginakatte, Kiran Aithal Balkudru
  • Dual inhibitors of TIM-3 and PD-1 pathways
    Patent number: 12226402
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Grant
    Filed: November 21, 2023
    Date of Patent: February 18, 2025
    Assignee: Aurigene Oncology Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Nagaraj Gowda
  • 1,2,4-Oxadiazole Derivatives as Immunomodulators
    Publication number: 20240400525
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Application
    Filed: June 19, 2024
    Publication date: December 5, 2024
    Applicant: Aurigene Oncology Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-oxadiazole derivatives as immunomodulators
    Patent number: 12037321
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Grant
    Filed: November 7, 2022
    Date of Patent: July 16, 2024
    Assignee: Aurigene Oncology Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds
    Patent number: 12005045
    Abstract: The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.
    Type: Grant
    Filed: November 22, 2023
    Date of Patent: June 11, 2024
    Assignee: AURIGENE ONCOLOGY LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS
    Publication number: 20240122904
    Abstract: The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.
    Type: Application
    Filed: November 22, 2023
    Publication date: April 18, 2024
    Inventors: Pottayil Govindan Nair SASIKUMAR, Muralidhara RAMACHANDRA, Seetharamaiah Setty Sudarshan NAREMADDEPALLI, Chennakrishnareddy GUNDALA
  • DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS
    Publication number: 20240100024
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: November 21, 2023
    Publication date: March 28, 2024
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Nagaraj Gowda
  • 1,2,4-Oxadiazole Derivatives as Immunomodulators
    Publication number: 20230167076
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Application
    Filed: November 7, 2022
    Publication date: June 1, 2023
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways
    Publication number: 20230144653
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Application
    Filed: January 5, 2023
    Publication date: May 11, 2023
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways
    Patent number: 11560403
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: January 24, 2023
    Assignee: AURIGENE ONCOLOGY LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • 1,2,4-oxadiazole derivatives as immunomodulators
    Patent number: 11512060
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: November 29, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS
    Publication number: 20220241248
    Abstract: The present invention relates to a composition of a CD47-SIRP? blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP? blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP? blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).
    Type: Application
    Filed: April 25, 2022
    Publication date: August 4, 2022
    Inventors: Muralidhara Ramachandra, Pottayil Govindan Nair Sasikumar, Girish Chandrappa Daginakatte, Kiran Aithal Balkudru
  • Combination of small molecule CD-47 inhibitors with other anti-cancer agents
    Patent number: 11311517
    Abstract: The present invention relates to a composition of a CD47-SIRP? blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP? blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP? blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: April 26, 2022
    Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Muralidhara Ramachandra, Pottayil Govindan Nair Sasikumar, Girish Chandrappa Daginakatte, Kiran Aithal Balkudru
  • 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling
    Patent number: 11274123
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 15, 2022
    Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS
    Publication number: 20210379024
    Abstract: The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.
    Type: Application
    Filed: March 13, 2019
    Publication date: December 9, 2021
    Inventors: Pottayil Govindan Nair SASIKUMAR, Muralidhara RAMACHANDRA, Seetharamaiah Setty Sudarshan NAREMADDEPALLI, Gundala Chennakrishnareddy
  • 1,2,4-Oxadiazole Derivatives as Immunomodulators
    Publication number: 20210198219
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Application
    Filed: March 4, 2021
    Publication date: July 1, 2021
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways
    Publication number: 20210139536
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Application
    Filed: January 22, 2021
    Publication date: May 13, 2021
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • 1,2,4-oxadiazole derivatives as immunomodulators
    Patent number: 10961205
    Abstract: The present invention relates to methods of modulating an immune response mediated by a PD-1 signaling pathway and of treating a cancer or an infectious disease. A subject is administered a compound(s) or a pharmaceutically acceptable salt or pharmaceutically acceptable composition thereof of formula (I) In the ring Q is S or O. R1 substituents are an optionally substituted side chain of the amino acid Ser or Thr and R3 substituents are a side chain of the amino acids Asn, Asp, Gln, or Glu. R2 is hydrogen or —CO-Aaa and Aaa is Thr or Ser with a free, amidated or esterified C-terminus. R4 and R5 are independently hydrogen or absent. R6 is hydrogen, alkyl or acyl.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: March 30, 2021
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli